Lates News

According to a quick report from Every AI, Dongguan Securities issued a research report on April 9, giving a "buy" rating to DeYuan Pharmaceutical (920735.SH). The reasons for the rating mainly include: 1) Revenue and profits both increased; 2) Operating expenses have increased somewhat; 3) Rapid growth in revenue from two main business lines; 4) The company has obtained multiple patents. (Daily Economic News)